Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Immuno-Oncology Overview 2017: CAR-T Cell Therapy Early Clinical Results are Extremely Promising -

Research and Markets
Posted on: 15 Feb 18

The "Immuno-Oncology Overview" report has been added to's offering.

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions.


  • The PD-1/PD-L1 inhibitor and TCR/CAR-T therapy drug classes lead the development of all immuno-oncology drugs. However, several novel mechanisms of action are also in early-phase development.
  • Developers of approved PD-1/PD-L1 inhibitors - Bristol-Myers Squibb, Merck & Co, Roche, AstraZeneca, and Pfizer - currently dominate the immuno-oncology field in terms of the number of ongoing, conducted, and planned trials.
  • Furthermore, PD-1/PD-L1 inhibitors remain a focal point of immuno-oncology combinations, with various types of combination approaches being studied.

Key Topics Covered:

  1. Executive Summary
  2. Immuno-Oncology Overview
  3. Current Status Of Immuno-Oncology Development
  4. Pd-1/Pd-L1 Inhibitors
  5. Ctla-4 Inhibitors
  6. Tcr And Car-T Therapies
  7. Ido Inhibitors
  8. Emerging Drug Classes
  9. Bristol-Myers Squibb
  10. Merck & Co
  11. Roche
  12. Astrazeneca
  13. Pfizer
  14. Immuno-Oncology Combinations
  15. Kol Survey
  16. Kol Interviews

For more information about this report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.